19/08/2026
Kenya’s pharmaceutical manufacturing sector has received a boost following the signing of a lease agreement between the Special Economic Zones Authority (SEZA) and Biopharma Limited, paving the way for the company to establish pharmaceutical manufacturing operations at the Naivasha Special Economic Zone.
Biopharma Limited has been licensed by SEZA to undertake pharmaceutical manufacturing within the Zone, marking an important step in the company’s expansion and SEZA’s efforts to attract investments in strategic sectors that strengthen Kenya’s industrial and healthcare value chains.
Biopharma is an established pharmaceutical company engaged in the development, manufacture and marketing of prescription medicines, over-the-counter (OTC) products and generic medicines. The company has a portfolio of more than 300 pharmaceutical products, with dosage forms including tablets, capsules, liquids, lotions, gels, ointments and creams.
The company places strong emphasis on quality and technology, incorporating quality checks across its production processes, from raw-material testing and manufacturing to packaging and distribution.
The investment at Naivasha SEZ is expected to support local pharmaceutical manufacturing, import substitution, technology and skills development, employment creation and Kenya’s ambition to become a competitive pharmaceutical manufacturing hub serving regional and African markets.
The project also aligns with Biopharma’s vision of becoming “Africa’s leading healthcare company by providing cost effective & high quality drugs to the people of Africa.”
The signing of the lease represents the transition from licensing to implementation and demonstrates the growing role of Naivasha SEZ as a destination for high-value manufacturing investments.
SEZA will be at hand to facilitate Biopharma through the investment implementation process while creating an enabling environment for manufacturers seeking to Make in Kenya for Africa and the World.